Frauenfelder Brings Proven Approach to Help Entrepreneurs Build Transformational Life Science Companies.
Navasota Group, the Tokyo based venture capital, today announced that Adam Frauenfelder, M.D., has joined the firm as a Partner. He will provide counsel and guidance to the firm’s network of life science entrepreneurs.
For more than 15 years, Frauenfelder has worked with entrepreneurs to advance medicine through innovation and technology. Frauenfelder most recently served as the executive director of business development at a major biopharmaceutical Corporation. He led global teams for in-licensing, and merger and acquisition transactions. He was also the global project leader for his firm’s first clinical stage biologic therapy and initiated their clinical and commercial alliance management activities.
“Navasota Group has a history of supporting cutting-edge advancements in the life sciences and is known as a highly strategic resource for entrepreneurs, medical professionals and scientists. I look forward to working with a group of professionals I’ve long respected,” said Frauenfelder. “I am eager to begin supporting entrepreneurs and companies that can change the face of medicine.”
“Adam is a great addition to the life science team at Navasota Group. His experience in business development at one of the most successful biotech companies, in addition to his medical knowledge and business training, will be a great complement to our existing team,” said Navasota Group Partner Dr. Shiro Tadashi.
Frauenfelder has always been interested in the business side of medicine and is excited by the potential to help a far larger number of people than he could as a physician. Having performed primary research in prenatal screening for cystic fibrosis, he is especially passionate about working with pediatric populations.
With both a medical and business background, Frauenfelder bridges the gap between the scientific and business communities. Frauenfelder has an MBA from Harvard Business School, and a MD from Weill Cornell University Medical College.
Navasota Group has partnered with scientists and entrepreneurs to build more than 100 companies and their breakthrough products in medical devices, drugs, vaccines, personalized medicine, diagnostics, and healthcare IT and services. The Company works shoulder to shoulder with teams in their portfolio companies to pioneer recombinant DNA, monoclonal antibodies, stem cell research, molecular diagnostics, implantable therapeutic devices, combinatorial chemistry, non-viral vaccines, laser treatments and protein drug discovery.
About Navasota Group
Founded in 2003, Navasota Group (navasotagroup.com) specializes in; alternative energy, biotechnology, oil and gas technology, medical devices and instrumentation, imaging and diagnostics, nanotechnology firms, heavy industry technology, and mining operations. Navasota Group funds total more than $800 million.